Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin

Phase 2

BAYER (BAYRY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Carcinoma, Hepatocellular

Clinical Trial

NCT00108953

Last updated: 12/19/2025

Regulatory Approvals

EMA7/19/2006

Nexavar

Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

View on EMA

Developer

BAYRY

BAYER

Healthcare•North America•NASDAQ

Related Pipeline

Regorafenib (Stivarga, BAY73- 4506)Phase 3

Colorectal Neoplasms

Amikacin Inhalation Solution (BAY41-6551)Phase 3

Pneumonia, Bacterial

Oxybutynin (Oxytrol, BAY839380)Phase 3

Overactive Bladder

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

EE20/DRSP (YAZ, BAY86-5300)Phase 3

Oral Contraceptive

View full pipeline